Janssen to Present Data from its Robust Oncology Portfolio and Pipeline at the 24th EHA Annual Congress
Results from DARZALEX® ▼ (daratumumab) Phase 3 CASSIOPEIA study in newly diagnosed transplant eligible patients with multiple myeloma selected for…